Relin Medicine (Relin), officially founded in 1996 with a belief of “pooling global resources to serve the healthcare industry in the Greater China Area”, features its strong academic promotion and has long been the sole distributor of many pharmaceutical MNEs. With advantages in ophthalmology and otolaryngology, Relin has gradually developed into a pharmaceutical enterprise that integrates new drug introductions, registrations, R&D, MAH and specialized academic promotions.

Relin is mainly running on its self-operated marketing model, but it also recruits sales agencies as a supplement. Relin is pound of its professional and specialized sales network, consisting of 34 branches and covering the entire country. As a leader in the ophthalmological prescription drug market, it has carefully chosen and successfully introduced many high-quality products into the Chinese market from the overseas. Through specialized academic promotions, Relin has brought 12 prescription drugs to the leading position, which seized the top market share in their respective categories. Given that the healthcare industry has been rapidly developing, Relin has already established its own retail business (OTC) division to fulfill the potential of the unique advantages of its main products. Over the years, HYLO- COMOD® (sodium hyaluronate eye drops) has risen as a one of the most successful products in the entire OTC field in China based on its excellent quality, accumulated prescription user bases and Relin’s modern media approach. Today, Relin has become a industry leader in raising public awareness for of eye health.

Since 2005, Relin has been been committing to self-run R&D with the goal of meeting clinical needs. As the world's first innovator to apply Levofloxacin in the field of otology, Relin obtained a new drug certificate and respective production license for this product named Zuofu® in China in 2009. This product has consistently taken the top market share due to its superior antibacterial effect. Through open and diverse international cooperation models, Relin has introduced andor invested in high-quality and high-potential new drugs worldwide. Among them includes,  the first-in-class new drug, MS-553, that has been selected as one of ‘the National Major Scientific and Technological Special Projects (the 12th Five-Year Plan) for Significant New Drugs Innovation and Development’. MS-553s international multi-center clinical trials are being conducted at various several globally renowned centers led by the Ohio State University (OSU), and significant clinical efficacy has been demonstrated in the Phase I/II clinical trials for several indications, including cancer, ocular fundi disease and autoimmune diseases. It is widely believed that MS-553 has promising prospects in the future.